



COMPANY INSPECTED BY CERTQUALITY
FOR THE COMPLIANCE TO
GMP
CODE OF FEDERAL REGULATION,
TITLE 21, VOLUME 2, PART 311



Labomar is attending the ISMO virtual investor conference

Istrana (TV), January 24, 2022. Labomar (Euronext Growth Milan, [Ticker: LBM](#)), nutraceutical company based in Italy with an international business, **on January 26** is attending “**ISMO - Italian Stock Market Opportunities Milan**”, a consolidated meeting opportunity between listed companies and the financial community which is organized by Banca IMI for the fifteenth consecutive year. The event, reserved to Institutional Investors, will take place in small group meetings lasting 50 minutes.

In this occasion, Labomar’s management team (BoD Member Claudio De Nadai, CFO Claudio Crespan and Head of Sales Francesco Da Riva) will share with the financial community the latest company news.

Materials dedicated to investors are available on the Company website www.labomar.com, “Investor” section.

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is a CDMO (Contract Development and Manufacturing Organization) engaged in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Its research team creates, develops and manufactures high added-value and innovative content nutraceutical products. Many of the supplements produced by Labomar leverage proprietary technologies which boost the bioavailability of the active ingredients, modulate their gastrointestinal absorption and improve their taste. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a high quality and productivity standard full service. The company boasts a well-structured and cutting-edge research and development department, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reported in 2020 preliminary consolidated revenues of approx. Euro 61.1 million (at like-for-like exchange rates approx. Euro 61.5 million), up 26.3% (27.2% at like-for-like exchange rates) on 2019. The 2020 figure includes - for the first time - the revenues and margins of the Canadian ImportFab for a full year, acquired in October 2019. Labomar SpA’s revenues in 2020 were approx. Euro 51.8 million (+10.2% vs 2019).

In July 2021, Labomar acquired 63% of the Welcare Group. The Group comprises Welcare Industries S.p.A. and Welcare Research S.r.l., producers of medical devices for skincare, with its registered office in Orvieto.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended its By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

For Information:

Labomar Press Office

Thanai Bernardini - +39.335.7245418 - me@thanai.it



COMPANY INSPECTED BY CERTQUALITY
FOR THE COMPLIANCE TO
GMP
CODE OF FEDERAL REGULATION,
TITLE 21, VOLUME 2, PART 311



Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it

Investor Relations Labomar

Claudio De Nadai - +39.0422.677203 - claudio.denadai@labomar.com

Mara Di Giorgio - +39.335.7737417 - mara@twin.services

Euronext Growth Advisor

Banca Mediolanum +39.02.9049 2525 - ecm@mediolanum.it